Of the 40 recertification units (RUs) required for a CRNI® to recertify, at least 30 RUs must be obtained by attending any INS Meeting (live or online). Up to 10 RUs may be earned from the non INS Meeting category. The learning assets in this section have all been approved for RUs. Virtual Conferences meet the INS Meeting (internal) criteria. Webinars meet the non INS Meeting (external) criteria. All webinars are free to INS members.

CRNI® Recertification Approved

Search by Category
Search by Format
Sort By
Search by Favorites
Search by Keyword

  • Webinar: Treatment and transitions of care for patients with cUTI
    Contains 2 Component(s) Includes a Live Web Event on 12/11/2024 at 1:00 PM (EST)

    This session will review the efficacy, safety, and administration of a potential treatment option for patients with cUTI and will describe the flexibility that this treatment option offers across sites of care within infusion services.

    THIS WEBINAR IS A LIVE EVENT ONLY | DECEMBER 11 at 1pm ET

    This session will review the efficacy, safety, and administration of a potential treatment option for patients with cUTI and will describe the flexibility that this treatment option offers across sites of care within infusion services.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    • Understand the efficacy and safety profile of a potential treatment option for patients with cUTI
    • Recognize the benefits of a treatment option for patients with cUTI across infusion services
    • Explain the preparation and administration of a potential treatment option for patients with cUTI



    Nikhil K. Bhayani, MD, FIDSA

    Assistant Professor

    Department of Internal Medicine, Anne Burnett Marion School of Medicine at Texas Christian University

    Nikhil K. Bhayani, MD, FIDSA, is an esteemed physician with over 18 years of experience in internal medicine and infectious disease. He has made major contributions to clinical practice, medical education, and research that have garnered him acclaim, including being named the 2024 Physician of the Year by Texas Health Harris Methodist Alliance Hospital, being the recipient of the 2021 Albert Nelson Marquis Lifetime Achievement Award, and numerous accolades awarded by the International Association of Top Professionals.

     
    Dr Bhayani is a graduate of the Ross University School of Medicine and holds a bachelor’s in biology from the University of Utah. He is currently an Assistant Professor at Anne Burnett Marion School of Medicine at Texas Christian University and an Infectious Diseases/Epidemiology Physician Advisor for the Department of Quality, Patient Safety, and Infection Prevention at Texas Health Resources, where he provides clinical guidance, supports quality improvement initiatives, and participates in multidisciplinary committees and projects. Dr Bhayani is deeply committed to improving health outcomes in the diverse patient population of the Dallas-Fort Worth area he serves, enhancing medical education, and contributing to the global fight against infectious diseases. 

  • Exploration of the Current State of PIVC Placement and Complications: Clinical Implications
    Contains 3 Component(s), Includes Credits

    This session will provide an overview of findings gleaned from a point prevalence study on PIVC placement and complications. Details regarding the study process and associated findings will be provided. Lessons learned and education and practice implications will also be explored.

    This session will provide an overview of findings gleaned from a point prevalence study on PIVC placement and complications. Details regarding the study process and associated findings will be provided. Lessons learned and education and practice implications will also be explored.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    ● Describe the process for a point prevalence study
    ● Discuss common findings gleaned from the point prevalence study
    ● Identify recommended practices to improve PIVC documentation and complication recognition

    Judy Smith, MSN, RN, CRNI®

    Judy Smith, MSN, RN, CRNI®, serves as Director of Vascular Access and Wound Care for Ascension Seton in Austin, Texas. She completed her BSN at the University of Texas at Austin in 1995 and her MSN in Healthcare Systems Management at Loyola University New Orleans in 2010. She has worked in the Vascular Access specialty for 21 years and published 2 research studies on disinfection of needleless connectors and 1 point prevalence study related to PIVC complications and documentation. She has presented at many Vascular Access and Infusion Therapy conferences in the United States and New Zealand. Judy enjoys reading and spending time with her family, especially her 2 grandsons.

    Vallire Hooper, PhD, RN, CPAN, FASPAN, FAAN

    Vallire Hooper, PhD, RN, CPAN, FASPAN, FAAN, is a Senior Nurse Scientist with Ascension. She has been a nurse for over 35 years, with a primary focus in perianesthesia nursing, working as a staff nurse, Clinical Nurse Specialist, and lastly, as a Clinical Nurse Scientist for the last 14 years. Dr Hooper obtained her PhD in Nursing from the Medical College of Georgia in 2009, with a research focus on factors influencing the multidisciplinary adoption of evidence-based clinical practice guidelines. She is a Fellow in the American Society of PeriAnesthesia Nurses as well as the American Academy of Nursing. Dr Hooper’s primary research interests include clinically focused patient outcomes research and factors influencing nursing care delivery.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: November 20, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Webinar: A Novel Echinocandin Treatment for Invasive Candidiasis
    Contains 2 Component(s)

    During the webinar, we will discuss unmet medical needs in the management of candidemia and invasive candidiasis, provide an overview of a next generation echinocandin, and review potential treatment scenarios and patient management considerations.

    THIS WEBINAR IS A LIVE EVENT ONLY | NOVEMBER 12 at 1pm ET

    During the webinar, we will discuss unmet medical needs in the management of candidemia and invasive candidiasis, provide an overview of a next generation echinocandin, and review potential treatment scenarios and patient management considerations.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    • Discuss unmet medical needs in the management of candidemia and invasive candidiasis
    • Provide an overview of a next-generation echinocandin
    • Discuss potential treatment scenarios and patient management considerations 


    PP-REZ-US-0343
    10/24

    Yvonne J. Burnett, PharmD, BCIDP

    Infectious Diseases Pharmacist and Regional Antimicrobial Stewardship Coordinator

    Yvonne J. Burnett, PharmD, BCIDP is an Infectious Diseases Pharmacist and Regional Antimicrobial Stewardship Coordinator at SSM Health for St. Louis University Hospital and Cardinal Glennon in St. Louis, MO. Dr. Burnett obtained her Doctor of Pharmacy degree from The University of Rhode Island and pursued residency training back in her home state of NJ at Atlantic Health System for her PGY1 and then South Texas Veterans Health Care System/University of Texas Health Science Center in San Antonio, TX for her PGY2 in Infectious Diseases. Prior to her current role at SSM Health, Dr. Burnett worked as an Associate Professor of Pharmacy Practice at St. Louis College of Pharmacy and held clinical appointments, first with the Division of Infectious Diseases at Washington University in St. Louis, leading the outpatient parenteral antimicrobial therapy team and, then as an infectious diseases and antimicrobial stewardship pharmacist at Missouri Baptist Medical Center. Dr. Burnett is board certified in Infectious Diseases Pharmacotherapy and is an active member of Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, and the Missouri and St. Louis Societies of Health-System Pharmacists. Dr. Burnett's practice and research interests include antimicrobial stewardship, outpatient parenteral antimicrobial therapy, and medical/pharmacy education and precepting. Outside of work, she enjoys traveling with friends, trying out the many great bars and restaurants St. Louis has to offer, and keeping up with her middle schooler and black Labrador.  

  • Extravasation Treatment: A Case Study Approach to Explore Options
    Contains 3 Component(s), Includes Credits Recorded On: 09/18/2024

    The treatment of an extravasation, the inadvertent delivery of a vesicant into the tissue around a vascular access device (VAD), is a source of patient harm that is under-recognized, under-reported, and thus likely ineffectively treated. Unfortunately, recommendations for extravasation treatment (primarily reliant on case reports) can be difficult to leverage into clear clinical guidelines, increasing the risk of inadequate or delayed post-extravasation monitoring and treatment. This presentation will review vesicant properties and their mechanisms of tissue injury, peripheral vs central VAD extravasation risks with related prevention measures, and recommended extravasation treatment strategies and resources using a case study approach.

    The treatment of an extravasation, the inadvertent delivery of a vesicant into the tissue around a vascular access device (VAD), is a source of patient harm that is under-recognized, under-reported, and thus likely ineffectively treated. Unfortunately, recommendations for extravasation treatment (primarily reliant on case reports) can be difficult to leverage into clear clinical guidelines, increasing the risk of inadequate or delayed post-extravasation monitoring and treatment. This presentation will review vesicant properties and their mechanisms of tissue injury, peripheral vs central VAD extravasation risks with related prevention measures, and recommended extravasation treatment strategies and resources using a case study approach.

    Objectives:

    • Describe the properties of the major vesicant categories that may precipitate tissue injury
    • Relate the relative extravasation risks of peripheral vs central VADS to extravasation prevention strategies
    • Describe current recommendations for treatment of selected vesicant extravasations, using a case study approach

    Barb Nickel, APRN-CNS, CCRN, CRNI®

    Barb Nickel, APRN-CNS, CCRN, CRNI®, is a Clinical Nurse Specialist, specializing in critical care and vascular access.  Her role includes staff development, quality improvement, and clinical consultation. She has presented nationally and published on infusion therapy. She was chair of the 2024 INS Standards of Practice Committee and is chair of the newly forming 2027 Standards of Practice Committee.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: September 18, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Oncology Infusion Therapy in Home and Ambulatory Sites of Service
    Contains 3 Component(s), Includes Credits Recorded On: 08/21/2024

    The need for alternate sites of care for oncology patients is growing with the expansion of the biologic drug portfolio. Insurance companies are shifting patients from hospital sites of service to independent providers, and the home and ambulatory clinic settings are now an attractive option for patients seeking more convenient sites for their infusions. In this session, we will outline the framework necessary to design an oncology infusion program, the policies and procedures necessary, and components of training needed to meet the challenges that serving this population of patients brings.

    The need for alternate sites of care for oncology patients is growing with the expansion of the biologic drug portfolio. Insurance companies are shifting patients from hospital sites of service to independent providers, and the home and ambulatory clinic settings are now an attractive option for patients seeking more convenient sites for their infusions. In this session, we will outline the framework necessary to design an oncology infusion program, the policies and procedures necessary, and components of training needed to meet the challenges that serving this population of patients brings.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • list the critical components necessary to provide safe infusion care for the oncology population
    • discuss the process used to determine medications’ appropriateness in the alternate infusion setting
    • describe key points for a training program to be used for nurses in the expansion of their skillset to include oncology
    • define effective communication methods and patterns to support the administration of oncology therapies in a setting outside of hospital outpatient facilities or physician office. 

    Pamela Jones McIntyre, MSN, RN, CRNI®, IgCN, OCN, VA-BC

    Pamela Jones McIntyre, MSN, RN, CRNI®, IgCN, OCN, VA-BC, has over 4 decades of comprehensive nursing experience. She is considered a subject matter expert in infusion therapy, with extensive experience operating ambulatory infusion clinics for specialty and oncology therapies, and 24 years of experience as an operator and Vice President of Clinical Services for home infusion. Recent projects have focused on expanding oncology biologic therapies to alternate sites of infusion, which Ms. McIntyre is determined to see accomplished safely and in the best interest of the patients and providers. She provides consulting services to health care organizations for infusion nursing program development and newly established ambulatory infusion centers through her LLC, Expert Infusion Nurse Consulting.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: August 21, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Implanted Vascular Access Devices: Back to the Basics in Care and Management
    Contains 3 Component(s), Includes Credits Recorded On: 06/11/2024

    Over 2 billion intravascular devices are inserted globally each year, and determining optimal maintenance protocols is challenging. Literature cites late complications of central venous access devices (CVAD) range from 7.2% to 32.1%. Implanted vascular access devices (IVADs) are quoted to have lower risk than other CVADs but are not risk-free. Despite risk, patients often retain their devices for extended periods. In this session, we will review the basics of care and management of IVADs and let evidence-based practice guide the way to minimizing potential complications.

    Over 2 billion intravascular devices are inserted globally each year, and determining optimal maintenance protocols is challenging. Literature cites late complications of central venous access devices (CVAD) range from 7.2% to 32.1%. Implanted vascular access devices (IVADs) are quoted to have lower risk than other CVADs but are not risk-free. Despite risk, patients often retain their devices for extended periods. In this session, we will review the basics of care and management of IVADs and let evidence-based practice guide the way to minimizing potential complications.  

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Identify best practices when accessing IVADs, including pre-assessment, skin preparation, needle access, and positioning. 
    • Discuss dressing changes and options available when patients have skin variables making dry and intact dressings difficult to achieve. 
    • Review how tubing changes vary dependent on the infusate.
    • Compare variances in flushing frequency and options related locking solutions.

    Mary Jo Sarver, MN, ARNP, AOCN, CRNI®, VA-BC, LNC

    CEO

    Sarver Better Living

    Mary Jo Sarver, MN, ARNP, AOCN, CRNI®, VA-BC, LNC, has more than 37 years of experience in infusion therapy and oncology/hematology care. Her role focuses on continuity of care and seamless transitions for patients within and outside the acute care setting. She collaborates and acts as a consultant locally and on a system level for Providence, guiding staff development, competency assessment, and process improvement to improve outcomes in multiple areas of clinical practice and new graduate transition to practice. She attends cancer care conferences, rounds in the clinics and hospital, and actively consults and sees patients and families for treatment and care planning. She has published, conducted research, and spoken on multiple topics within the United States. For decades, passion has prompted her to participate both locally on the Puget Sound Infusion Nurses Society (PSINS), Puget Sound Oncology Nursing Society (PSONS), and American Cancer Society (ACS) boards and to nationally assume various roles through the Infusion Nurses Society (INS) and Oncology Nursing Society) (ONS). She is CEO of Sarver Better Living Products LLC, a family-run company.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: June 11, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • INS 2024 Virtual Conference
    Contains 19 Product(s)

    INS 2024 Virtual Conference will provide a great alternative for those who are not able to attend the in-person event. Participants will have the ability to attend 18 select sessions virtually and on-demand. This option also enables CRNI®s to earn up to 36 recertification units (RUs). The virtual conference will include some of the sessions in the Vascular Access Device (VAD) Track devoted to an important aspect of infusion therapy, vascular access devices as well as sessions included in the Alternative Care Setting Track dedicated to the care of patients outside of acute care settings.

    INS 2024 Virtual Conference will provide a great alternative for those who are not able to attend the in-person event. Participants will have the ability to attend 18 select sessions virtually and on-demand. This option also enables CRNI®s to earn up to 36 recertification units (RUs). The virtual conference will include some of the sessions in the Vascular Access Device (VAD) Track devoted to an important aspect of infusion therapy, vascular access devices as well as sessions included in the Alternative Care Setting Track dedicated to the care of patients outside of acute care settings.

  • Minimizing the Risk of Drug Diversion
    Contains 3 Component(s), Includes Credits Recorded On: 05/08/2024

    Controlled substances diversion (CSD) is a risk for any organization that prescribes, stores, dispenses, or administers controlled substances. CSD can lead to patient safety issues, including inadequate patient pain relief, harm to the nurse, and a significant liability risk to the organization. The American Nurses Association estimates that 6% to 8% of nurses have a substance abuse problem that impacts their practice. Some contributing factors to the issue of CSD include the global pandemic, nurses with easy access to medications, and lack of intravenous product standardization. A multidisciplinary approach to reduce the risk of CSD should include drug diversion prevention, diversion program standards and policies, and monitoring and reporting procedures. Strategies to promote diversion prevention include dose sizes that eliminate waste and use of pre-filled syringes in ready-to-administer (RTA) form. RTA medications are recommended by The Joint Commission, the Institute for Safe Medication Practices (ISMP), the American Society of Health-System Pharmacists (ASHP), and the Anesthesia Patient Safety Foundation (APSF). In this session, we will discuss the issue of CSD, contributing factors, prevention methods, and monitoring and reporting programs.

    image

    Controlled substances diversion (CSD) is a risk for any organization that prescribes, stores, dispenses, or administers controlled substances. CSD can lead to patient safety issues, including inadequate patient pain relief, harm to the nurse, and a significant liability risk to the organization. The American Nurses Association estimates that 6% to 8% of nurses have a substance abuse problem that impacts their practice. Some contributing factors to the issue of CSD include the global pandemic, nurses with easy access to medications, and lack of intravenous product standardization. A multidisciplinary approach to reduce the risk of CSD should include drug diversion prevention, diversion program standards and policies, and monitoring and reporting procedures. Strategies to promote diversion prevention include dose sizes that eliminate waste and use of pre-filled syringes in ready-to-administer (RTA) form. RTA medications are recommended by The Joint Commission, the Institute for Safe Medication Practices (ISMP), the American Society of Health-System Pharmacists (ASHP), and the Anesthesia Patient Safety Foundation (APSF). In this session, we will discuss the issue of CSD, contributing factors, prevention methods, and monitoring and reporting programs. 

    Learning Objectives: At the conclusion of this session, the learner will be able to:
    • Discuss the prevalence and contributing factors to CSD.
    • Describe the impact of CSD upon patients, clinicians, and the organization.
    • Identify strategies to promote diversion prevention, including RTA medications and dose sizes.
    • Discuss CSD prevention policies, standards, monitoring and reporting programs.

    Evan Frasure, PharmD, BCPS

    Evan S. Frasure III, PharmD, BCPS, is the Director for Controlled Substance Diversion Prevention for Duke University Health System, where he oversees the diversion prevention efforts across Duke Health. Dr. Frasure graduated from pharmacy school at Idaho State University in 2007 and completed a PGY1 residency at Carolinas Medical Center – NorthEast in Concord, NC. He has held various positions during his time at Duke, including continuity of care, administration, and business services oversight. He started in his current role in March 2017. In this role, he has implemented staff education modules, a diversion oversight committee, and updated policies & procedures and an analytics software program. Many of these changes have been the result of learning from Drug Enforcement Administration (DEA) settlements.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: May 8, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • An Innovative Instructional Simulation Strategy for PIVC Insertion Training
    Contains 3 Component(s), Includes Credits Recorded On: 04/10/2024

    Despite being one of the most common invasive medical devices, peripheral intravenous catheters (PIVC) fail at unacceptably high rates, with around 50% to 75% failing before treatment is complete. The development of nursing professionals’ expertise is essential in reducing failures and complications associated with PIVC use. Proper training is necessary to acquire professional expertise in strategies that ensure an accurate performance and minimize the risks inherent to the procedure. Even though PIVC insertions are a prevalent, technically complex, and invasive procedure, most health care practitioners receive little substantive PIVC education, training, or opportunities to practice skills to become competent. In addition, PIVC training can vary between professionals and curriculums. In some countries, technical professionals without higher education, such as licensed practical nurses (LPN), are part of the nursing team and are licensed to perform PIVC insertions. In this session, we will discuss an innovative instructional simulation strategy for PIVC insertion training used with LPNs to improve performance and reduce complications associated with the procedure.

    Despite being one of the most common invasive medical devices, peripheral intravenous catheters (PIVC) fail at unacceptably high rates, with around 50% to 75% failing before treatment is complete. The development of nursing professionals’ expertise is essential in reducing failures and complications associated with PIVC use. Proper training is necessary to acquire professional expertise in strategies that ensure an accurate performance and minimize the risks inherent to the procedure. Even though PIVC insertions are a prevalent, technically complex, and invasive procedure, most health care practitioners receive little substantive PIVC education, training, or opportunities to practice skills to become competent. In addition, PIVC training can vary between professionals and curriculums. In some countries, technical professionals without higher education, such as licensed practical nurses (LPN), are part of the nursing team and are licensed to perform PIVC insertions. In this session, we will discuss an innovative instructional simulation strategy for PIVC insertion training used with LPNs to improve performance and reduce complications associated with the procedure.

    Learning Objectives: At the conclusion of this session, learners will be able to:
    1. Describe clinicians’ PIVC insertion performance from the perspective of patient safety.
    2. Present an innovative instructional simulation strategy for PIVC insertion training.
    3. Discuss how innovative educational simulation strategies for training PIVC insertion among health care professionals can improve performance and reduce complications associated with the procedure.

    Juliana Faria Campos, PhD, RN

    Dr. Juliana Faria Campos is an intensive care specialist, an associate professor at the Department of Fundamental Nursing at Escola de Enfermagem Anna Nery, Universidade Federal do Rio de Janeiro (EEAN/UFRJ), and a permanent professor of the master's and doctoral programs in nursing at EEAN/UFRJ. She is a research leader of the Research Group Technologies and Conceptions for the Systematization of Nursing Care (TECCONSAE), a coordinator of the Laboratory of Skills and Clinical Simulation at UFRJ, and a reviewer of scientific journals. She holds a PhD in nursing, and has experience in intensive care nursing and health training, working mainly on clinical simulation, simulated training, and deliberate practice in rapid cycles.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: April 10, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Infusion Properties and their Role in Determining the Most Appropriate Vascular Access Device
    Contains 3 Component(s), Includes Credits Recorded On: 03/06/2024

    Did you know that the properties of Infusion therapy play a crucial role in determining the most appropriate vascular access device for patients? They are critical factors to consider and can have a significant impact on patient care and outcomes. By understanding the importance of these properties, we can ensure that our patients receive the best possible treatment. During this session, we will explore this topic further to ensure we provide the best care for our patients.

    image

    Did you know that the properties of Infusion therapy play a crucial role in determining the most appropriate vascular access device for patients? They are critical factors to consider and can have a significant impact on patient care and outcomes. By understanding the importance of these properties, we can ensure that our patients receive the best possible treatment. During this session, we will explore this topic further to ensure we provide the best care for our patients.

    Learning Objectives: At the conclusion of this session, learners will be able to:

    • Define up-to-date clinical standards of pharmacokinetics of vascular infusions, medications, and treatment as relates to patient safety and vessel preservation.
    • Identify evidence-based practices for potential complications of peripheral and central vascular access devices.
    • Discuss clinical indications, evaluations, and rationales for evidence-based practice regarding vessel preservation complexities.
    • Discuss clinical indicators related to evidence-based practice for vascular access devices and their complications in various patient populations.

    Carla Dillard, MSN, RN, VA-BC

    Carla is the current chief nursing officer for Dynamic Access. She is responsible for overseeing the clinical and regulatory compliance of the organization. Carla has been with Dynamic since 2005 and has held various leadership roles in the development of clinical, operational, and educational components of the organization. Before joining Dynamic, Carla worked as a registered nurse in acute care emergency and intensive care units. She established an educational company in 2013 to address deficiencies in clinical bedside care. Motivated by her passion for education, Carla remains dedicated to bridging these gaps.

    Katie Nesbitt, PharmD, BCPS

    Katie Nesbitt, PharmD, BCPS, received her Doctorate in Pharmacy from Philadelphia College of Pharmacy and completed a PGY1 general pharmacy residency at Tower Health Network in Reading, Pennsylvania.  After working at Tower Health Network for 5 years, she transitioned into a clinical pharmacy specialist role focused in cardiology and anticoagulation at Lehigh Valley Health Network. She currently serves as a clinical pharmacy consultant for RxToolKit.  Dr. Nesbitt is a board-certified pharmacotherapy specialist. Utilizing her current roles and experiences, she is able to pursue her passion for educating in areas including critical care pharmacotherapy and cardiology-related medication topics.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: March 6, 2027

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.